arGentis Pharmaceuticals, LLC Receives Favorable Opinion for European Orphan Drug Designation

Published: Jan 06, 2009

MEMPHIS, Tenn.--(BUSINESS WIRE)--arGentis Pharmaceuticals, LLC announced today that the European Medicines Agency’s (EMEA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending the company’s product candidate ARG201 (native type 1 bovine collagen) for the treatment of diffuse systemic sclerosis, also known as systemic scleroderma (SSc) for designation as an orphan medicinal product to the European Commission.

Back to news